Klinik für Urologie und Kinderurologie, Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg, Baldingerstraße, 35043, Marburg, Deutschland.
Several studies discussing the pathology of overactive bladder suggested changes in urinary proteins. The neurotrophin "nerve growth factor" (NGF) seems to be an important marker in overactive bladder syndrome (OAB). In this prospectively designed study we evaluated NGF blood levels (sNGF) initially and after injection of botulinum toxin type A (BTX-A) in the detrusor muscle in patients suffering from idiopathic OAB.
Blood samples were obtained from 26 patients (66.5 years, 28-83) with idiopathic OAB. sNGF levels were measured before and 4 weeks after BTX-A treatment by enzyme-linked immunosorbent assay (ELISA). A group of 32 healthy persons with normal bladder function served as controls (41 years, 19-60). sNGF was evaluated in relation to clinical data and the severity of OAB (wet/dry).
Significantly higher sNGF levels were detected in patients with OAB compared to the control group (58.8 vs 2.0 pg/ml, p< 0.005). Further, sNGF levels were elevated in patients with wet OAB compared to patients with dry OAB (85.0 vs 0.73 pg/ml, p< 0.005). Patients > 60 years showed significantly higher sNGF levels (77.2 vs 8.9 pg/ml, p< 0.05) compared to younger OAB patients. After BTX-A therapy sNGF levels decreased significantly compared to baseline (p< 0.005).
NGF appears to play a decisive role in OAB. Its use as a biomarker in both the diagnostics and follow-up after therapy seems promising. To what extent sNGF can be useful as a biomarker or in therapy monitoring needs to be examined prospectively in a larger population.
Article in German.
Written by:
Knippschild S, Frohme C, Olbert P, Hofmann R, Hegele A. Are you the author?
Reference: Urologe A. 2011 Oct 8. Epub ahead of print.
doi: 10.1007/s00120-011-2726-0
PubMed Abstract
PMID: 21979907
UroToday.com Overactive Bladder (OAB) Section
